APPLICATION
ANDA091272
TYPE
ANDA
ORIGINAL APPROVAL
2010-08-18
LATEST ACTION
2025-09-02
ROUTE
ORAL
DOSAGE FORM
TABLET, EXTENDED RELEASE
MARKETING STATUS
Discontinued
Products
VENLAFAXINE HYDROCHLORIDEDiscontinued
VENLAFAXINE HYDROCHLORIDE EQ 225MG BASE · TABLET, EXTENDED RELEASE · ORAL
VENLAFAXINE HYDROCHLORIDEDiscontinued
VENLAFAXINE HYDROCHLORIDE EQ 75MG BASE · TABLET, EXTENDED RELEASE · ORAL
VENLAFAXINE HYDROCHLORIDEDiscontinued
VENLAFAXINE HYDROCHLORIDE EQ 150MG BASE · TABLET, EXTENDED RELEASE · ORAL
VENLAFAXINE HYDROCHLORIDEDiscontinued
VENLAFAXINE HYDROCHLORIDE EQ 37.5MG BASE · TABLET, EXTENDED RELEASE · ORAL
Approval history
2025-09-02Labeling · Supplement 33 · standardAP
2025-09-02Labeling · Supplement 28 · standardAP
2019-03-29Labeling · Supplement 15 · standardAP
2019-03-29Manufacturing (CMC) · Supplement 18 · unknownAP
2019-03-29Labeling · Supplement 14 · standardAP
2014-12-10Labeling · Supplement 10 · standardAP
2014-03-03Labeling · Supplement 7 · standardAP
2012-06-26Labeling · Supplement 3 · standardAP
2010-08-18OriginalAP
Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.
Weekly Briefing
Read a past issue →Get the Weekly GxP Briefing
Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.